ProCE Banner Activity

TRANSFORM: Lisocabtagene Maraleucel vs Salvage Chemotherapy Followed by ASCT as Second-Line Treatment in Relapsed/Refractory Large B-Cell Lymphoma

Slideset Download
Conference Coverage
Significant and clinically meaningful improvement in EFS was observed with liso-cel vs SoC as second-line therapy in patients with LBCL refractory to or relapsed ≤12 months after first-line therapy.

Released: December 21, 2021

Expiration: December 20, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation